Advertisement
U.S. markets open in 9 hours 18 minutes

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.37-0.60 (-3.00%)
At close: 04:00PM EDT
19.77 +0.40 (+2.07%)
After hours: 06:48PM EDT

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees487

Key Executives

NameTitlePayExercisedYear Born
Mr. Barry E. GreenePresident, CEO & Director1.29MN/A1963
Ms. Kimi E. Iguchi CPACFO & Treasurer665.37k144.99k1962
Ms. Anne Marie Cook Esq.Senior VP, General Counsel & Secretary711.6kN/A1962
Mr. Christopher BenecchiChief Business Officer703.76kN/A1972
Dr. Laura Gault M.D., Ph.D.Chief Medical Officer334.08kN/AN/A
Mr. Matt LasmanisChief Technology & Innovation OfficerN/AN/AN/A
Mr. Mike QuirkChief Scientific OfficerN/AN/AN/A
Ashley KaplowitzDirector of Investor RelationsN/AN/AN/A
Ms. Erin E. LancianiChief People & Experience OfficerN/AN/A1969
Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sage Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.